Nineteen children with cystic fibrosis and aged between 5 and 13 years were randomized to receive two doses at monthly intervals of either a split-virion influenza vaccine (MFV-Ject, Institut Merieux) or a sub-unit vaccine (Fluvirin, Evans). In those completing the study, there was a satisfactory serological response. There was no statistically significant difference between the immunogenicity of the two vaccines as evaluated by haemagglutination inhibition or single radial haemolysis tests. The incidence of local side-effects was similar in the two groups.
Get full access to this article
View all access options for this article.
References
1.
EftimiouJHodsonETaylorP: Importance of viruses and Legionella pneumophila in respiratory exacerbations of young adults with cystic fibrosis. Thorax1984; 39: 150–154.
2.
PetersenNTHoibyCHMordhorstK: Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma–possible synergism withPseudomonas aeruginosa. Acta Paediatr Scand1981; 70: 623–628.
3.
HowellsCHVesselinova-JenkinsCKEvansAD: Influenza vaccination and mortality from bronchopneumonia in the elderly. Lancet1975; i: 381–383.
4.
SmithJWGPollardR: Vaccination against influenza, a five year study in the Post Office. J Hyg1979; 83: 157–170.
5.
GrossPA: Reactogenicity and immunogenicity of bivalent influenza vaccine in one- and two-dose trials in children: a summary. J Infect Dis1977; 136 (suppl): S616–S625
6.
Concepts and Procedures for Laboratory-based Influenza Surveillance. US Department of Health and Human Sciences.
7.
SchildGCPereiraMSChakravertyP: Single-radial haemolysis: a new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiological surveillance of influenza. Bull WHO1975; 52: 43–50.
